Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,112 questions in 171 reviews · Eyes and Vision
current versionsNo studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intravitreal triamcinolone acetonide injection 4 mg vs macular laser Cataract progression ‐ 9 to 24 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 2.68 [2.21, 3.24] | NR | Moderate |
Intravitreal triamcinolone acetonide injection 4 mg vs macular laser Use of IOP‐lowering medications ‐ 9 to 24 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 3.92 [2.59, 5.96] | NR | Moderate |
Intravitreal dexamethasone implant 0.7 mg vs sham Change of retinal thickness ‐ 36 months (negative is better) · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | 1 study · 701 participants | Moderate |
Intravitreal triamcinolone acetonide injection 4 mg vs macular laser Surgery for glaucoma ‐ 9 to 24 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 11.68 [0.63, 216] | NR | Low |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Gain of three or more lines visual acuity · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Change in central retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Cataract progression · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Use of IOP‐lowering medications · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | Low |
Intravitreal triamcinolone acetonide injection 4 mg vs antiVEGF Surgery for glaucoma · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravitreal dexamethasone implant 0.7 mg vs sham Cataract progression ‐ 36 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 3.89 [2.75, 5.5] | 1 study · 697 participants | Moderate |
Intravitreal dexamethasone implant 0.7 mg vs sham Use of IOP‐lowering medications ‐ 36 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 4.54 [3.19, 6.46] | 1 study · 697 participants | Moderate |
Intravitreal dexamethasone implant 0.7 mg vs sham Surgery for glaucoma ‐ 36 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 5.04 [0.59, 42.95] | 1 study · 697 participants | Low |
Intravitreal dexamethasone implant 0.7 mg vs intravitreal antiVEGF Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | Moderate |
Intravitreal dexamethasone implant 0.7 mg vs intravitreal antiVEGF Gain of three or more lines visual acuity ‐ 12 months · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | RR 0.99 | NR | Low |
Intravitreal dexamethasone implant 0.7 mg vs intravitreal antiVEGF Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes Intravitreal steroids for macular edema in diabetes (2020) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Change in the visual field (short term) · participants with glaucoma or intraocular hypertension Acupuncture for glaucoma (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Intervention NR Reduction in IOP (short term) · participants with glaucoma or intraocular hypertension Acupuncture for glaucoma (2020) · Cochrane | no estimate extracted | 3 studies · 137 participants | Very low |
Intervention NR Change in visual acuity (short term) · participants with glaucoma or intraocular hypertension Acupuncture for glaucoma (2020) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |
Intervention NR Progression of optic disc damage or nerve fiber layer loss (short term) · participants with glaucoma or intraocular hypertension Acupuncture for glaucoma (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Intervention NR Adverse events (short term) · participants with glaucoma or intraocular hypertension Acupuncture for glaucoma (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Silicone oil vs sulfur hexafluoride (SF6) Visual acuity ≥ 5/200 at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 1.57 [0.93, 2.66] | 1 study · 87 participants | Low |
Silicone oil vs perfluropropane (C3F8) Retina detachment at 3 years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs perfluropropane (C3F8) Visual acuity worse than 20/200 (regardless of anatomic outcome) at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs perfluropropane (C3F8) Intraocular pressure (IOP) greater than 21 mmHg · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs perfluropropane (C3F8) Visually significant cataract at 3 years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs perfluropropane (C3F8) Quality of life measures at 3 years evaluated using validated scale as reported by study · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard silicone oil vs heavy silicone oil Change in visual acuity (logMAR) at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | 1 study · 93 participants | Low |
Standard silicone oil vs heavy silicone oil Macular attachment at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard silicone oil vs heavy silicone oil Retinal detachment at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 0.89 [0.54, 1.48] | 1 study · 186 participants | Low |
Standard silicone oil vs heavy silicone oil Visual acuity worse than 20/200 (regardless of anatomic outcome) at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard silicone oil vs heavy silicone oil Intraocular pressure (IOP) greater than 21 mmHg at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Macular attachment at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 1.37 [1.01, 1.86] | 1 study · 87 participants | Low |
Standard silicone oil vs heavy silicone oil Visually significant cataract at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard silicone oil vs heavy silicone oil Quality of life measures at two years evaluated using validated scale as reported by study at one year · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
5000‐centistoke vs 1000‐centistoke Change in visual acuity (logMAR) at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
5000‐centistoke vs 1000‐centistoke Macular attachment at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
5000‐centistoke vs 1000‐centistoke Retina detachment ‐ After removal of silicone oil at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 0.36 [0.08, 1.67] | 1 study · 85 participants | Low |
5000‐centistoke vs 1000‐centistoke Visual acuity worse than 20/200 (regardless of anatomic outcome) at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
5000‐centistoke vs 1000‐centistoke Intraocular pressure (IOP) greater than 21 mmHg at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 0.9 [0.41, 1.94] | 1 study · 86 participants | Low |
5000‐centistoke vs 1000‐centistoke Visually significant cataract at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 1.3 [0.89, 1.89] | 1 study · 86 participants | Low |
5000‐centistoke vs 1000‐centistoke Quality of life measures at 18 months evaluated using validated scale as reported by study · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Retina detachment at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Visual acuity worse than 20/200 (regardless of anatomic outcome) at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Intraocular pressure greater than 21 mmHg at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Visually significant cataract at two years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs sulfur hexafluoride (SF6) Quality of life measures at two years evaluated using validated scale as reported by study · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Silicone oil vs perfluropropane (C3F8) Visual acuity ≥ 5/200 at 3 years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 0.97 [0.73, 1.31] | 1 study · 264 participants | Low |
Silicone oil vs perfluropropane (C3F8) Macular attachment at 3 years · surgery for retinal detachment associated with proliferative vitreoretinopathy Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy (2020) · Cochrane | RR 1 [0.86, 1.15] | 1 study · 264 participants | Low |
Psychological therapies and/or group programmes vs waiting list or no care Health‐related quality of life · adults (>= 18 years) with an irreversible visual impairment Low vision rehabilitation for better quality of life in visually impaired adults (2020) · Cochrane | no estimate extracted | 1 study · 54 participants | Very low |